Safety by Design—Mitigating the Risk of Medication Errors Through Product Design

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-04-15-2014
Volume 2014 eBook
Issue 1

Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.

 

The increasing prevalence and high cost of medication errors have prompted regulators and manufacturers to look into the role of product design in ensuring the safe and correct use of medicines. Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.

Download

Pharmaceutical Technology’s 2014 Solid Dosage and Excipients eBook

.

 

 

 

 

Articles in this issue
PTe0414_Colorcon.jpg
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
PTe0414_controlled.jpg
Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators
pte0414_hausnervideo.jpg
Continuous Manufacturing for Solid-Dosage Drug Production
PTe0414_Hovione.jpg
A Practical Guide to Hot-Melt Extrusion Scale-Up for Pharmaceutical Applications
PTe0414_ModWave.jpg
Using Modular Systems in Solid-Dosage Manufacturing
pte0414_Martinvideo.jpg
Advances in Hot-Melt Extrusion Manufacturing
PTe0414_Bohle.jpg
Obtaining User-Defined Particle Size Distribution Using Dry Granulation
PTe0414_evonik.jpg
A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
PTe0414Generic.jpg
Selection of Excipients in Generic Formulations
Recent Videos
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

EMA’s CHMP Gives Positive Opinion for Use of Lecanemab in Early Alzheimer’s Disease

Felicity Thomas
November 16th 2024
Article

CHMP has granted Eisai Europe and Biogen a positive opinion for the use of their monoclonal antibody therapy in treating early Alzheimer’s disease.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Avantor Sees Future of Opportunities with Growing Development of Next-Gen Biotherapeutics

Feliza Mirasol
November 15th 2024
Article

Executives at Avantor talk about the future of the biopharmaceutical industry and the anticipated impact that a wave of next-generation biotherapeutics will bring.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Bespak and Orbia Fluor & Energy Materials Collaborate on Climate-Friendly Inhalers

Susan Haigney
November 8th 2024
Article

The companies will work to create climate-friendly pMDIs using Orbia’s low global warming potential propellant.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Oblenio Bio Created by Aditum Bio and Leads Biolabs to Develop Therapeutic Antibody for Treating Autoimmune Disorders

Feliza Mirasol
November 8th 2024
Article

In the collaboration, the new company, Oblenio Bio, has been granted an exclusive option to license LBL-051, a tri-specific T-cell engager antibody, from Leads Biolabs.